We tested this hypothesis by dose titrating a panel of four BRAFV600E-CRC cell lines (HT-29, LS411N, MDST8, and SW1417) with vemurafenib (BRAFi), in the presence or absence of TGFα, HGF, and bFGF, ligands for the receptors EGFR, c-MET, and FGFR, respectively, (Fig. 2f). Here, FGF2 is linked to colorectal carcinoma.